Evidence map›Paper›PMID 33895402›Full record

ArticleTransplantation and cellular therapy2021

Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

Neel S Bhatt, Ruta Brazauskas, Rachel B Salit, Karen Syrjala, Stephanie Bo-Subait, Heather Tecca, Sherif M Badawy, K Scott Baker, Amer Beitinjaneh, Nelli Bejanyan and 43 more

Open access · bronzeAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.Advances in experimental medicine and biology · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 5 countries.

Neel S BhattClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: nbhatt@fredhutch.org.
Ruta BrazauskasCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
Rachel B SalitClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Karen SyrjalaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Stephanie Bo-SubaitCenter for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Heather TeccaCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Sherif M BadawyDivision of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Amer BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami, Miami, Florida.
Nelli BejanyanDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Michael ByrneVanderbilt University Medical Center, Nashville, Tennessee.
Ajoy DiasBeth Israel Deaconess Medical Center, Boston, Massachusetts.
Nosha FarhadfarDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.
César O FreytesTexas Transplant Institute, San Antonio, Texas.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Shahrukh HashmiDepartment of Internal Medicine, Mayo Clinic, Minnesota; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
Robert J HayashiDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.
Sanghee HongBlood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Kareem JamaniTom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Kimberly A KasowUniversity of North Carolina, Chapel Hill, North Carolina.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
Maxwell M KremMarkey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
Catherine J LeeUtah Blood and Marrow Transplant Program at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Stephanie LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Navneet S MajhailBlood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Adriana K MaloneTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
David I MarksAdult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Lih-Wen MauCenter for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Samantha J MayoLawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
Lori S MufflyDivision of Blood and Marrow Transplantation, Stanford University, Stanford, California.
Sunita NathanSection of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, Illinois.
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Kristin M PageDivision of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina.
Jaime PreusslerCenter for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Hemalatha G RangarajanDepartment of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's hospital, Columbus, Ohio.
Seth J RotzDepartment of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's Hospital, Cleveland, Ohio.
Nina SaloojaImperial College London, London, United Kingdom.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Raquel SchearsUniversity of Central Florida, Department of Emergency Medicine, Orlando, Florida.
Tal Schechter-FinkelsteinHospital for Sick Children, Toronto, Ontario Canada.
Gary SchillerHematological Malignancy/Stem Cell Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, California.
Ami J ShahDivision of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, California.
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Trent WangDivision of Transplantation and Cellular Therapy, University of Miami, Miami, Florida.
Baldeep WirkPenn State Cancer Institute, Bone Marrow Transplant Program, Hershey, Pennsylvania.
Minoo BattiwallaSarah Cannon Blood Cancer Network, Nashville, Tennessee.
Hélène SchoemansDepartment of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Betty HamiltonBlood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
David BuchbinderDivision of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.
Rachel PhelanCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Bronwen ShawCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Fred Hutch Cancer Center · USMedical College of Wisconsin · USPenn State Milton S. Hershey Medical Center · USSt. Jude Children's Research Hospital · USNational Marrow Donor Program · USChildren's Hospital of Orange County · USKU Leuven · BELucile Packard Children's Hospital · USMoffitt Cancer Center · USWinnMed · USBeth Israel Deaconess Medical Center · USCHRISTUS Transplant Institute · USCleveland Clinic · USFlorida College · USHospital for Sick Children · CAHuntsman Cancer Institute · USMayo Clinic in Florida · USNationwide Children's Hospital · USNorthwestern University · USRush University Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
Improving Survivorship Care for Adolescents and Young Adults: a Mixed Methods Study of Alignment with the National Standards for Survivorship CareU01CA246659 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S · 2020 to 2025
$3.6M
NCATS NIH HHS UL1 TR001422NCI NIH HHS R01 CA215134NCI NIH HHS U01 CA246659NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted this study to assess the post-HCT work status of survivors of allogeneic HCT who underwent HCT as YAs and to analyze the patient-, disease-, and HCT-related factors associated with their work status at 1 year post-HCT. Using Center for International Blood and Marrow Transplant Research data, we evaluated the post-HCT work status (full-time, part-time work, unemployed, or medical disability) of 1365 YA HCT survivors who underwent HCT between 2008 and 2015. Percentages of work status categories were reported at 4 time points: 6 months, 1 year, 2 years, and 3 years post-HCT. Percentages of post-HCT work status categories at the 1-year time point were also described in relation to survivors' pre-HCT work status categories. Factors associated with 1-year post-HCT work status (full-time or part-time work) were examined using logistic regression. From 6 months to 3 years post-HCT, the percentage of survivors working full-time increased from 18.3% to 50.7% and the percentage working part-time increased from 6.9% to 10.5%. Of patients in full-time work pre-HCT, 50% were unemployed or on medical disability at 1 year post-HCT. Female sex (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.40 to 0.77), HCT Comorbidity Index score ≥3 (OR, 0.57; 95% CI, 0.39 to 0.82), pre-HCT unemployment (OR, 0.37; 95% CI, 0.24 to 0.56), medical disability (OR, 0.44; 95% CI, 0.28 to 0.70), development of grade III-IV acute graft-versus-host disease (OR, 0.52; 95% CI, 0.34 to 0.80), and relapse within 1 year post-HCT (OR, 0.34; 95% CI, 0.21 to 0.56) were associated with a lower likelihood of employment at 1 year post-HCT. Compared with myeloablative conditioning (MAC) with total body irradiation (TBI), MAC without TBI (OR, 1.71; 95% CI, 1.16 to 2.53) was associated with a greater likelihood of employment at 1 year post-HCT. Graduate school-level education (OR, 2.47; 95% CI, 1.49 to 4.10) was also associated with a greater likelihood of employment at 1 year post-HCT. Although the work status among YA HCT survivors continued to improve over time, a substantial subset became or remained unemployed or on medical disability. These findings underscore the need for effective interventions to support return to work in this population.

Indexed as

Hematopoietic Stem Cell TransplantationReturn to WorkFemaleHumansNeoplasm Recurrence, LocalSurvivorsTransplantation, HomologousUnited StatesYoung AdultHematopoietic cell transplantationQuality of lifeReturn to workYoung adult

Identifiers

PMID33895402
PMCPMC8425287
OpenAlexW3157866779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.